Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Journey Medical (DERM) Net Income towards Common Stockholders: 2020-2025

Historic Net Income towards Common Stockholders for Journey Medical (DERM) over the last 5 years, with Sep 2025 value amounting to -$2.3 million.

  • Journey Medical's Net Income towards Common Stockholders rose 3.14% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.5 million, marking a year-over-year increase of 53.41%. This contributed to the annual value of -$14.7 million for FY2024, which is 280.79% down from last year.
  • Per Journey Medical's latest filing, its Net Income towards Common Stockholders stood at -$2.3 million for Q3 2025, which was up 38.04% from -$3.7 million recorded in Q2 2025.
  • Journey Medical's 5-year Net Income towards Common Stockholders high stood at $16.8 million for Q3 2023, and its period low was -$21.8 million during Q4 2021.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$3.4 million (2024), whereas its average is -$2.6 million.
  • As far as peak fluctuations go, Journey Medical's Net Income towards Common Stockholders tumbled by 36,810.34% in 2021, and later soared by 266.56% in 2023.
  • Over the past 5 years, Journey Medical's Net Income towards Common Stockholders (Quarterly) stood at -$21.8 million in 2021, then soared by 51.07% to -$10.6 million in 2022, then surged by 79.86% to -$2.1 million in 2023, then spiked by 173.82% to $1.6 million in 2024, then grew by 3.14% to -$2.3 million in 2025.
  • Its last three reported values are -$2.3 million in Q3 2025, -$3.7 million for Q2 2025, and -$4.1 million during Q1 2025.